NEWS

Team marks milestone in progress toward investigational new drug for triple-negative breast cancer

New inhibitor improves response to chemotherapy in preclinical models

A new compound developed by researchers at MUSC Hollings Cancer Center shows promise in overcoming chemotherapy resistance in triple-negative breast cancer – and could potentially be applied to fibrotic conditions like liver fibrosis or pulmonary fibrosis.

At the center of this work is preventing the protein lysyl oxidase, or LOX, from going overboard in doing its job and, therefore, helping to produce a “stiff,” or desmoplastic, environment around tumors.

Read about the research here.